Review
Version 1
Preserved in Portico This version is not peer-reviewed
Role of Immunotherapy in Sarcomas
Version 1
: Received: 14 December 2023 / Approved: 14 December 2023 / Online: 14 December 2023 (16:46:14 CET)
A peer-reviewed article of this Preprint also exists.
Dalal, S.; Shan, K.S.; Thaw Dar, N.N.; Hussein, A.; Ergle, A. Role of Immunotherapy in Sarcomas. Int. J. Mol. Sci. 2024, 25, 1266. Dalal, S.; Shan, K.S.; Thaw Dar, N.N.; Hussein, A.; Ergle, A. Role of Immunotherapy in Sarcomas. Int. J. Mol. Sci. 2024, 25, 1266.
Abstract
Sarcomas are a group of malignancies of mesenchymal origin with plethora of subtypes. Given the sheer heterogeneity of various subtypes and rarity of the disease, management of sarcomas has been challenging with poor patient outcomes. Surgery, radiation therapy and chemotherapy have remained the backbone of treatment in patients with sarcoma. The introduction of immunotherapy has rev-olutionized the treatment of various solid and hematological malignancies. In this review, we discuss basics of immunotherapy and immune microenvironment in sarcomas, various modalities of im-munotherapy such as immune checkpoint blockade, oncolytic viruses, cancer targeted antibodies, vaccine therapy and adoptive cell therapies like CAR T-cell therapy, T cell therapy, TCR therapy.
Keywords
Immunotherapy; sarcomas; adoptive cell therapy; CAR T-cell therapy; oncolytic viruses; TCR therapy; immune microenvironment.
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
